ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1032

Causes of Death Among Populations with Systemic Lupus Erythematosus by Race and Ethnicity

Tiffany Taylor1, Christine Anastasiou1, Stephanie Rush1, Laura Trupin2, Maria Dall'Era3, Patricia Katz1, Kamil Barbour4, Jinoos Yazdany1 and Milena Gianfrancesco1, 1University of California San Francisco, San Francisco, CA, 2UC San Francisco, San Francisco, CA, 3University of California San Francisco, Corte Madera, CA, 4Centers for Disease Control, Atlanta, GA

Meeting: ACR Convergence 2021

Keywords: Cardiovascular, Epidemiology, Mortality, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with manifestations that vary widely in severity. Data indicate that minority populations are at higher risk of developing SLE and have more severe outcomes, including mortality. However, whether specific causes of death vary by race and ethnicity has largely been unexplored, particularly for Asians and Hispanics.

Methods: The California Lupus Surveillance Project identified potential SLE cases using community rheumatology and nephrology clinics, community hospitals, and integrated healthcare systems among individuals who were residents of San Francisco County, CA during January 1, 2007 – December 31, 2009. SLE cases were defined using American College of Rheumatology Classification Criteria (≥4 of the 11 revised criteria as defined in 1982 and updated in 1997) or two alternative definitions: SLE diagnosed by the patient’s treating rheumatologist plus 3 ACR criteria; or lupus-related kidney disease (World Health Organization class II-VI lupus nephritis upon biopsy or documented record of SLE diagnosis and dialysis or renal transplantation). Cases were matched to the 2007-2017 National Death Index (NDI) data, which included the underlying cause of death for each individual. Chi-squared tests were used to examine differences in underlying cause of death by race (white, Black, Asian), ethnicity (Hispanic, non-Hispanic), and sex (female, male). Age-standardized mortality ratios (SMRs) between SLE patients and the general San Francisco county population were calculated for the leading cause of death, and estimated observed versus expected deaths by sex, race, and Hispanic/Latino ethnicity.

Results: During the study time period, 812 deaths related to SLE were identified. Cardiovascular disease (CVD) was the leading cause of death among SLE patients overall (33%), and across all racial and ethnic groups. Other top causes included rheumatic disease (18%) and hematological/oncological conditions (18%) overall, and across all racial groups. Overall, CVD as the underlying cause of death was over three times higher among SLE cases than in the general population of San Francisco County (SMR=3.63) (Table 1). CVD deaths for those with SLE were nearly four times higher for Asians and over six times higher for Hispanic/Latinos. CVD deaths were also elevated for females (SMR=4.7) and males (SMR=3.5) with SLE compared with their non-SLE counterparts.

Conclusion: These findings indicate that CVD is the leading underlying cause of death among SLE patients across various racial and ethnic groups, and that SLE patients experience a disproportionate burden of CVD mortality compared with the general population.

Taylor_Abstract.jpeg”


Disclosures: T. Taylor, None; C. Anastasiou, None; S. Rush, None; L. Trupin, None; M. Dall'Era, AstraZeneca, 2, Aurinia, 2, Biogen, 2, Bristol Myers Squibb, 2, GlaxoSmithKline, 2, Pfizer, 2; P. Katz, None; K. Barbour, None; J. Yazdany, Pfizer, 2, Astra Zeneca, 5, Eli Lilly, 2, University of California, San Francisco, 3; M. Gianfrancesco, None.

To cite this abstract in AMA style:

Taylor T, Anastasiou C, Rush S, Trupin L, Dall'Era M, Katz P, Barbour K, Yazdany J, Gianfrancesco M. Causes of Death Among Populations with Systemic Lupus Erythematosus by Race and Ethnicity [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/causes-of-death-among-populations-with-systemic-lupus-erythematosus-by-race-and-ethnicity/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/causes-of-death-among-populations-with-systemic-lupus-erythematosus-by-race-and-ethnicity/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology